BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells

  • Park, Youngsook (Division of Biological Sciences, Sookmyung Women's University) ;
  • Kim, Jongmin (Division of Biological Sciences, Sookmyung Women's University)
  • Received : 2018.12.19
  • Accepted : 2019.01.08
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

The role of tumor-proximal factors in tumor plasticity during chemoresistance and metastasis following chemotherapy is well studied. However, the role of endothelial cell (EC) derived paracrine factors in tumor plasticity, their effect on chemotherapeutic outcome, and the mechanism by which these paracrine factors modulate the tumor microenvironment are not well understood. In this study, we report a novel mechanism by which endothelial miR-125a and let-7e-mediated regulation of interleukin-6 (IL-6) signaling can manipulate vasculogenic mimicry (VM) formation of MDA-MB-231 breast cancer cells. We found that endothelial IL-6 levels were significantly higher in response to cisplatin treatment, whereas levels of IL-6 upon cisplatin exposure remained unchanged in MDA-MB-231 breast cancer cells. We additionally found an inverse correlation between IL-6 and miR-125a/let-7e expression levels in cisplatin treated ECs. Interestingly, IL-6, IL-6 receptor (IL-6R), and signal transducer and activator of transcription 3 (STAT3) genes in the IL-6 pathway are closely regulated by miR-125a and let-7e, which directly target its 3' untranslated region. Functional analyses revealed that endothelial miR-125a and let-7e inhibit IL-6-induced adhesion of monocytes to ECs. Furthermore, conditioned medium from cisplatin treated ECs induced a significantly higher formation of VM in MDA-MB-231 breast cancer cells as compared to that from intact ECs; this effect of cisplatin treatment was abrogated by concurrent overexpression of miR-125a and let-7e. Overall, this study reveals a novel EC-tumor cell crosstalk mediated by the endothelial miR-125a/let-7e-IL-6 signaling axis, which might improve chemosensitivity and provide potential therapeutic targets for the treatment of cancer.

Keywords

References

  1. Abdullah LN and Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2, 3 https://doi.org/10.1186/2001-1326-2-3
  2. Holen KD and Saltz LB (2001) New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2, 290-297 https://doi.org/10.1016/S1470-2045(00)00324-7
  3. O'Reilly EA, Gubbins L, Sharma S et al (2015) The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 3, 257-275 https://doi.org/10.1016/j.bbacli.2015.03.003
  4. Bleau AM, Hambardzumyan D, Ozawa T et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235 https://doi.org/10.1016/j.stem.2009.01.007
  5. Zhou W, Fong MY, Min Y et al (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501-515 https://doi.org/10.1016/j.ccr.2014.03.007
  6. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70 https://doi.org/10.1016/S0092-8674(00)81683-9
  7. Deanfield JE, Halcox JP and Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115, 1285-1295 https://doi.org/10.1161/CIRCULATIONAHA.106.652859
  8. Lee A, Papangeli I, Park Y et al (2017) A PPARgammadependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. Sci Rep 7, 2528 https://doi.org/10.1038/s41598-017-02852-4
  9. Jo HN, Kang H, Lee A et al (2017) Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. BMB Rep 50, 384-389 https://doi.org/10.5483/BMBRep.2017.50.7.085
  10. Butler JM, Kobayashi H and Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10, 138-146 https://doi.org/10.1038/nrc2791
  11. Gilbert LA and Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366 https://doi.org/10.1016/j.cell.2010.09.043
  12. Folberg R and Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112, 508-525 https://doi.org/10.1111/j.1600-0463.2004.apm11207-0810.x
  13. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE and Hendrix MJ (2012) Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 18, 2726-2732 https://doi.org/10.1158/1078-0432.CCR-11-3237
  14. Cao Z, Bao M, Miele L, Sarkar FH, Wang Z and Zhou Q (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49, 3914-3923 https://doi.org/10.1016/j.ejca.2013.07.148
  15. Wagenblast E, Soto M, Gutierrez-Angel S et al (2015) A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520, 358-362 https://doi.org/10.1038/nature14403
  16. Hendrix MJ, Seftor EA, Hess AR and Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3, 411-421 https://doi.org/10.1038/nrc1092
  17. Williamson SC, Metcalf RL, Trapani F et al (2016) Vascu logenic mimicry in small cell lung cancer. Nat Commun 7, 13322 https://doi.org/10.1038/ncomms13322
  18. Bharti R, Dey G and Mandal M (2016) Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Lett 375, 51-61 https://doi.org/10.1016/j.canlet.2016.02.048
  19. Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH and Kroep JR (2012) Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 18, 3816-3827 https://doi.org/10.2174/138161212802002797
  20. Rossi JF, Lu ZY, Jourdan M and Klein B (2015) Interleukin-6 as a therapeutic target. Clin Cancer Res 21, 1248-1257 https://doi.org/10.1158/1078-0432.CCR-14-2291
  21. Wang Y, Niu XL, Qu Y et al (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295, 110-123 https://doi.org/10.1016/j.canlet.2010.02.019
  22. Hong L, Sharp T, Khorsand B et al (2016) MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. PLoS One 11, e0160915 https://doi.org/10.1371/journal.pone.0160915
  23. Zhang W, Shen X, Xie L, Chu M and Ma Y (2015) Micro-RNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells. J Inflamm (Lond) 12, 18 https://doi.org/10.1186/s12950-015-0061-8
  24. Hunter CA and Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16, 448-457 https://doi.org/10.1038/ni.3153
  25. Kanda T and Takahashi T (2004) Interleukin-6 and cardiovascular diseases. Jpn Heart J 45, 183-193 https://doi.org/10.1536/jhj.45.183
  26. Chen SC, Chang YL, Wang DL and Cheng JJ (2006) Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br J Pharmacol 148, 226-232 https://doi.org/10.1038/sj.bjp.0706647
  27. Zhang GJ and Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19, 1427-1432
  28. Nakashima J, Tachibana M, Horiguchi Y et al (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6, 2702-2706
  29. Seymour JF, Talpaz M, Cabanillas F, Wetzler M and Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13, 575-582 https://doi.org/10.1200/JCO.1995.13.3.575
  30. Jansson MD and Lund AH (2012) MicroRNA and cancer. Mol Oncol 6, 590-610 https://doi.org/10.1016/j.molonc.2012.09.006
  31. Kim J (2018) MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology. BMB Rep 51, 65-72 https://doi.org/10.5483/BMBRep.2018.51.2.011
  32. Lee A, McLean D, Choi J, Kang H, Chang W and Kim J (2014) Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep 47, 311-317 https://doi.org/10.5483/BMBRep.2014.47.6.085
  33. Kang H, Park Y, Lee A et al (2017) Negative regulation of NOD1 mediated angiogenesis by PPARgamma-regulated miR-125a. Biochem Biophys Res Commun 482, 28-34 https://doi.org/10.1016/j.bbrc.2016.11.032
  34. Li Z, Pan W, Shen Y et al (2018) IGF1/IGF1R and micro- RNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. Cell Cycle 17, 1212-1219 https://doi.org/10.1080/15384101.2018.1469873
  35. Shan Y, Liu Y, Zhao L, Liu B, Li Y and Jia L (2017) MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1. Int J Biochem Cell Biol 90, 48-58 https://doi.org/10.1016/j.biocel.2017.07.016
  36. Xiao M, Cai J, Cai L et al (2017) Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res 10, 24 https://doi.org/10.1186/s13048-017-0321-8
  37. Zhu WY, Luo B, An JY et al (2014) Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest 32, 394-401 https://doi.org/10.3109/07357907.2014.922569
  38. Huang P, Mao LF, Zhang ZP et al (2018) Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer. Thyroid 28, 613-623 https://doi.org/10.1089/thy.2017.0401
  39. Naidu S, Shi L, Magee P et al (2017) PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Sci Rep 7, 15441 https://doi.org/10.1038/s41598-017-14843-6
  40. Lu G, Ma Y, Jia C et al (2017) Reduced miR-125a levels associated with poor survival of patients with hepatocellular cancer. Oncol Lett 14, 5952-5958
  41. McCall MN, Kent OA, Yu J, Fox-Talbot K, Zaiman AL and Halushka MK (2011) MicroRNA profiling of diverse endothelial cell types. BMC Med Genomics 4, 78 https://doi.org/10.1186/1755-8794-4-78
  42. Sun M, Guo S, Yao J et al (2019) MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells. J Cell Biochem 120, 1894-1902 https://doi.org/10.1002/jcb.27503
  43. Zhang Y, Zhang Q, Gui L et al (2018) Let-7e inhibits TNF-alpha expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. J Cell Physiol 233, 8605-8616 https://doi.org/10.1002/jcp.26576
  44. Schnegg CI, Yang MH, Ghosh SK and Hsu MY (2015) Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma. Cancer Res 75, 1682-1690 https://doi.org/10.1158/0008-5472.CAN-14-1855
  45. van der Schaft DW, Seftor RE, Seftor EA et al (2004) Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96, 1473-1477 https://doi.org/10.1093/jnci/djh267